The Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee discussed on the approval and recommendations for two diabetic drugs. The committee voted against any harsh measures, recommending only that information from two neutral clinical trials with the drugs be added to the drugs' labels and rejected withdrawal or new restrictions. The trials on two DPP-4 inhibitors, saxagliptin and alogliptin, concluded that the ...
Read More
You have just read an article categorized health
titled Two Diabetes Drugs Show Neutral Results for Cardiovascular Benefits.
Written by:
editor -
Thursday, April 16, 2015
There are currently no comments for "Two Diabetes Drugs Show Neutral Results for Cardiovascular Benefits"
Post a Comment